Search

Your search keyword '"Rorick, Tyrus"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Rorick, Tyrus" Remove constraint Author: "Rorick, Tyrus"
24 results on '"Rorick, Tyrus"'

Search Results

1. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

3. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

4. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

5. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)

7. Supplement to: Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

8. Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials

9. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial

10. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

11. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

12. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

13. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

14. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

15. The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study.

18. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

19. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes

20. REDUCTION OF MYOCARDIAL INFARCTION WITH VORAPAXAR: RESULTS FROM THE TRA·CER TRIAL

21. PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL

22. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.

23. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes

24. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Catalog

Books, media, physical & digital resources